Category
February 28, 2019
Trevi R Mancilla, and Gregory J Aune Abstract The oldest cohort of childhood cancer survivors is entering into their sixth decade. The milestone comes with the knowledge that this population is at 15 times greater risk of cardiovascular events than the general population. One factor in this is doxorubicin, a chemotherapeutic drug commonly used to treat […]
February 26, 2019
Siyuan Zheng, PhD, assistant professor in the Department of Epidemiology and Biostatistics in the Long School of Medicine, has received a Rising STARs Award from the UT System. The award for early-career investigators comes with a $250,000 grant.
February 26, 2019
Samuel A. Kotler, Vitali Tugarinov, Thomas Schmidt, Alberto Ceccon, David S. Libich, Rodolfo Ghirlando, Charles D. Schwieters, and G. Marius Clore Abstract The N-terminal region of the huntingtin protein, encoded by exon-1, comprises an amphiphilic domain (httNT), a polyglutamine (Q n ) tract, and a proline-rich sequence. Polyglutamine expansion results in an aggregation-prone protein responsible for Huntington’s disease. Here, we study the earliest events […]
February 22, 2019
The Cancer Prevention and Research Institute of Texas has awarded 54 new academic research, prevention and product development grants totaling nearly $96 million. San Antonio’s cut is $3 million. All three Alamo City grants will support research at UT Health San Antonio. They include a pair of $900,000 awards and one for $1.2 million. Dr. Yuzuru […]
February 22, 2019
Ewing sarcoma research Yuzuru Shiio, MD, PhD, of the Greehey Children’s Cancer Research Institute at UT Health San Antonio, was awarded $1.2 million to further studies of Ewing sarcoma, a pediatric bone and soft tissue cancer. The median age of Ewing sarcoma patients is 15 years, and more than half of patients are adolescents. Dr. […]
February 6, 2019
By studying the outcomes of more than 28,000 long-term childhood cancer survivors in the United States and Europe, researchers found that exposure to different anthracyclines results in variable long-term cardiovascular risk.
February 4, 2019
Tabrez A. Mohammad, Yun S. Tsai, Safwa Ameer, Hung-I Harry Chen, Yu-Chiao Chiu & Yidong Chen Abstract Background Cell lines form the cornerstone of cell-based experimentation studies into understanding the underlying mechanisms of normal and disease biology including cancer. However, it is commonly acknowledged that contamination of cell lines is a prevalent problem affecting biomedical science and available methods for cell […]
February 3, 2019
Jorge J. De La Chapa, Prajjal K. Singha, Kristen K. Self, McKay L. Sallaway, Stanton F. McHardy, Matthew J. Hart, Howard Stan McGuff, Matthew C. Valdez Francisco Ruiz II, Srikanth R. Polusani, Cara B. Gonzales Abstract Background Oral squamous cell carcinoma (OSCC) is a deadly disease with a mere 40% five‐year survival rate for patients with advanced disease. Previously, we discovered that capsazepine [...]January 31, 2019
In an interview with Oncology Learning Network, Gregory J. Aune, MD, Assistant Professor of Pediatrics at UT Health San Antonio and Greehey Children’s Cancer Research Institute, discussed his team’s findings from a multicenter study evaluating the long-term risk for anthracycline-related cardiomyopathy in survivors of childhood cancer (JAMA Oncol. 2019 Jan 31. Epub ahead of print).
January 31, 2019
Gregory Aune, MD, PhD, of UT Health San Antonio, served on a team that found different chemotherapy drugs used to treat children with cancer appear to have different risks long term for cardiomyopathy (abnormal heart muscle with impaired function). The study was in more than 28,000 childhood cancer survivors. Credit: UT Health San Antonio In […]